159 related articles for article (PubMed ID: 33920868)
1. IDO1-Targeted Therapy Does Not Control Disease Development in the Eµ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia.
Öztürk S; Kalter V; Roessner PM; Sunbul M; Seiffert M
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33920868
[TBL] [Abstract][Full Text] [Related]
2. Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia
Atene CG; Fiorcari S; Mesini N; Alboni S; Martinelli S; Maccaferri M; Leonardi G; Potenza L; Luppi M; Maffei R; Marasca R
Front Immunol; 2022; 13():832263. PubMed ID: 35371054
[TBL] [Abstract][Full Text] [Related]
3. TBET-expressing Th1 CD4
Roessner PM; Hanna BS; Öztürk S; Schulz R; Llaó Cid L; Yazdanparast H; Scheffold A; Colomer D; Stilgenbauer S; Lichter P; Seiffert M
Br J Haematol; 2020 Apr; 189(1):133-145. PubMed ID: 31724172
[TBL] [Abstract][Full Text] [Related]
4. Meta-Analysis Reveals Significant Sex Differences in Chronic Lymphocytic Leukemia Progression in the
Koch M; Reinartz S; Saggau J; Knittel G; Rosen N; Fedorchenko O; Thelen L; Barthel R; Reinart N; Seeger-Nukpezah T; Reinhardt HC; Hallek M; Nguyen PH
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32698538
[TBL] [Abstract][Full Text] [Related]
5. Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs.
Volarevic V; Markovic BS; Jankovic MG; Djokovic B; Jovicic N; Harrell CR; Fellabaum C; Djonov V; Arsenijevic N; Lukic ML
Theranostics; 2019; 9(20):5976-6001. PubMed ID: 31534532
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients.
Öztürk S; Paul Y; Afzal S; Gil-Farina I; Jauch A; Bruch PM; Kalter V; Hanna B; Arseni L; Roessner PM; Schmidt M; Stilgenbauer S; Dietrich S; Lichter P; Zapatka M; Seiffert M
Leukemia; 2022 Feb; 36(2):464-475. PubMed ID: 34417556
[TBL] [Abstract][Full Text] [Related]
7. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
[TBL] [Abstract][Full Text] [Related]
8. A Specific CD44lo CD25lo Subpopulation of Regulatory T Cells Inhibits Anti-Leukemic Immune Response and Promotes the Progression in a Mouse Model of Chronic Lymphocytic Leukemia.
Goral A; Firczuk M; Fidyt K; Sledz M; Simoncello F; Siudakowska K; Pagano G; Moussay E; Paggetti J; Nowakowska P; Gobessi S; Barankiewicz J; Salomon-Perzynski A; Benvenuti F; Efremov DG; Juszczynski P; Lech-Maranda E; Muchowicz A
Front Immunol; 2022; 13():781364. PubMed ID: 35296093
[TBL] [Abstract][Full Text] [Related]
9. CD73 Promotes Chronic Lymphocytic Leukemia.
Allard D; Chrobak P; Bareche Y; Allard B; Tessier P; Bergeron MA; Johnson NA; Stagg J
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804900
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer.
Wu C; Spector SA; Theodoropoulos G; Nguyen DJM; Kim EY; Garcia A; Savaraj N; Lim DC; Paul A; Feun LG; Bickerdike M; Wangpaichitr M
Cancer Metab; 2023 May; 11(1):7. PubMed ID: 37226257
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T cells contribute to the immunosuppressive phenotype of neutrophils in a mouse model of chronic lymphocytic leukemia.
Goral A; Sledz M; Manda-Handzlik A; Cieloch A; Wojciechowska A; Lachota M; Mroczek A; Demkow U; Zagozdzon R; Matusik K; Wachowska M; Muchowicz A
Exp Hematol Oncol; 2023 Oct; 12(1):89. PubMed ID: 37817276
[TBL] [Abstract][Full Text] [Related]
12. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.
Efanov A; Zanesi N; Nazaryan N; Santanam U; Palamarchuk A; Croce CM; Pekarsky Y
Leukemia; 2010 May; 24(5):970-5. PubMed ID: 20357824
[TBL] [Abstract][Full Text] [Related]
13. CD74 is dispensable for development of chronic lymphocytic leukemia in
Barthel R; Fedorchenko O; Velmans T; Rosen N; Nguyen PH; Reinart N; Florin A; Herling M; Hallek M; Fingerle-Rowson G
Leuk Lymphoma; 2020 Dec; 61(12):2799-2810. PubMed ID: 32667245
[TBL] [Abstract][Full Text] [Related]
14. Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
Poncelet L; Ait-Belkacem R; Marillier R; Gomes B; Stauber J
J Pharm Biomed Anal; 2019 Jun; 170():220-227. PubMed ID: 30933897
[TBL] [Abstract][Full Text] [Related]
15. Role of the splenic microenvironment in chronic lymphocytic leukemia development in Eµ-TCL1 transgenic mice.
Collard JP; McKenna MK; Noothi SK; Alhakeem SS; Rivas JR; Rangnekar VM; Muthusamy N; Bondada S
Leuk Lymphoma; 2022 Aug; 63(8):1810-1822. PubMed ID: 35258388
[TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.
Li A; Barsoumian HB; Schoenhals JE; Cushman TR; Caetano MS; Wang X; Valdecanas DR; Niknam S; Younes AI; Li G; Woodward WA; Cortez MA; Welsh JW
Cancer Lett; 2018 Sep; 431():54-63. PubMed ID: 29746927
[TBL] [Abstract][Full Text] [Related]
17. The Tumor Microenvironment-Dependent Transcription Factors AHR and HIF-1α Are Dispensable for Leukemogenesis in the Eµ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia.
Gonder S; Largeot A; Gargiulo E; Pierson S; Fernandez Botana I; Pagano G; Paggetti J; Moussay E
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572746
[TBL] [Abstract][Full Text] [Related]
18. Biological and clinical significance of tryptophan-catabolizing enzymes in cutaneous T-cell lymphomas.
Maliniemi P; Laukkanen K; Väkevä L; Dettmer K; Lipsanen T; Jeskanen L; Bessede A; Oefner PJ; Kadin ME; Ranki A
Oncoimmunology; 2017; 6(3):e1273310. PubMed ID: 28405495
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
McClanahan F; Hanna B; Miller S; Clear AJ; Lichter P; Gribben JG; Seiffert M
Blood; 2015 Jul; 126(2):203-11. PubMed ID: 25800048
[TBL] [Abstract][Full Text] [Related]
20. Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice.
Tang CH; Chang S; Hashimoto A; Chen YJ; Kang CW; Mato AR; Del Valle JR; Gabrilovich DI; Hu CC
Cancer Immunol Res; 2018 Jun; 6(6):696-710. PubMed ID: 29650518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
